Royalty Report: Drugs, Biotechnology, Disease – Collection: 26631


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Biotechnology
  • Disease
  • Therapeutic
  • Kidneys
  • Medical
  • Device

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26631

License Grant
We entered into a License Agreement with a nonprofit corporation, to develop a new, more potent and longer acting form of the anemia drug Erythropoietin, or EPO.
License Property
EPO is a glycoprotein naturally made by the body to stimulate red blood cell production; the currently marketed forms are manufactured using recombinant DNA technology and are used to treat anemia or low blood cell count.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 263771

License Grant
Licensor grants an irrevocable, non-exclusive, freely sublicensable license, to make, have made, import, use, sell, and offer for sale throughout the world, Peginesatide and Products under any and all rights in the Arbitration Patents.
License Property
The Product shall mean any product comprising or containing Peginesatide.

The patents relate to Peginesatide.

Peginesatide shall mean Licensees proprietary compound known as peginesatide, including any derivative, fragment, variant, prodrug, metabolite, degradation product, oxidation product, ester, stereoisomer, hydrate, solvate, salt form or radio-labeled form thereof.

Field of Use
Treatment of anemia associated with chronic kidney disease.

IPSCIO Record ID: 4553

License Grant
The University granted us a non-exclusive license to a) a patent application and any patents that grant therefrom; and b) the right to use a biological material, in a specific field of use, for commercial development, production and marketing of certain products.
License Property
TARGT technology is based upon a transduced tissue microorgan (MO) that acts as an autologous protein or peptide “bioreactor” created from a small (1/2 the size of a toothpick) piece of the patient’s dermal tissue explanted and reimplanted in a simple procedure under local anesthetic.

TARGTEPO is an endogenous Erythropoietin (EPO) secretion TARGT for treatment of End-Stage Renal Disease (ESRD) and other indications requiring EPO treatment such as ß-thalassemia. Erythropoietin (EPO) is a protein that is naturally secreted by the kidneys and functions to stimulate the bone marrow to produce red blood cells. End-Stage Renal Disease (ESRD) is a condition where the kidneys have completely stopped functioning.

IPSCIO Record ID: 26640

License Grant
Japanese Licensor hereby grants an exclusive licence to Canadian Licensee to market and produce the Products.
License Property
The Products shall comprise, but not be limited to, the following
·Recombinant Human Interferon alpha-2a (rHulFN-a 2a) and alpha-2b (rHulFN-a 2b)
·Recombinant Human granulocyte colony stimulating factor (rHuG-CSF);
·Recombinant Human granulocyte macrophage colony stimulating factor (rHuGM-CSF);
·Interleukin 2
·EPO (erythropoietin)

The Company has acquired license to patented technologies related to the production of therapeutic proteins, alpha and beta interferon, Interleukin 2, EPO (erythropoietin) and human growth factors (rHuG-CSF and rHuGM-CSF).

Field of Use
Field of Use relates to the medical industry.

IPSCIO Record ID: 27386

License Grant
The Japanese Company hereby grants an exclusive license to make in one location, have made and use Licensed Know-how, Patents and Products in the Licensed Territory in the Licensed Field and to sell Licensed Products in the Licensed Territory in the Licensed Field.
License Property
Technology relating to erythropoietin and processes for its manufacture.  561,024 Materials Applied to Microbial Expression of Erythropoietin; 582, Materials Applied to Microbial Expression of Erythropoietin; etc.
Field of Use
Licensed Field shall mean and include EPO for all indications for human use except diagnostics.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.